


RECEIPT



SCH
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
ATTORNEYS AT LAW
1100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934
TELEPHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com

ROBERT GREENE STERNE STEVEN R. LUDWIG
EDWARD J. KESSLER ROBERT C. COVERT*
JORGE A. GOLDSTEIN LINDA E. ALCORN
SAMUEL L. FOX ROBERT C. MILLONIG
DAVID K.S. CORNWELL MICHAEL V. MESSINGER
ROBERT W. EDMOND JUDITH U. KIM
TRACY-GENE G. DURKIN TIMOTHY J. SHEA, JR.
MICHELE A. CIMBALA DONALD R. MCPHAIL
MICHAEL B. RAY PATRICK E. GARRETT
ROBERT E. SOKOHL STEPHEN G. WHITESIDE
ERIC K. STEFFE JEFFREY T. HELVEY*
MICHAEL O. LEE HEIDI L. KRAUS

JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER
JEFFREY S. WEAVER

KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
ALBERT J. FASULO II*
W. BRIAN EDGE*
ELDORA ELLISON FLOYD*
W. RUSSELL SWINDELL
THOMAS C. FIALA

KAREN R. MARKOWICZ**
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
ELIZABETH J. HAANES**
MARK P. TERRY**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

December 14, 2000

WRITER'S DIRECT NUMBER:

(202) 371-2637

INTERNET ADDRESS:

KAREN.M@SKGF.COM

Box: Office of Initial Patent
Examination's Customer
Service Center

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 09/617,116; Filed: July 14, 2000
For: **Folylpolyglutamyl Synthetase Gene Transfer to
Enhance Antifolate Drug Sensitivity**
Inventors: AGHI *et al.*
Our Ref: 0609.4830001/JAG/KRM

TECH CENTER 1600/2900
MAR 08 2001

RECEIVED

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Corrected Official Filing Receipt (*in duplicate*);
2. Copy of Official Filing Receipt with the corrections in red ink noted thereon; and
3. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 14, 2000
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

JAG/KRM/awt
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

AGHI *et al.*

Appl. No. 09/617,116

Filed: July 14, 2000

For: **Folylpolyglutamyl Synthetase
Gene Transfer to Enhance
Antifolate Drug Sensitivity**



RECEIVED
MAR 08 2001
U.S. CH CENTER 1600
JAG/KRM

Art Unit: 1614

Examiner: *To Be Assigned*

Atty. Docket: 0609.483000 JAG/KRM

Request for Corrected Official Filing Receipt

Commissioner for Patents
Washington, D.C. 20231

Attn: Office of Initial Patent
Examination's Customer
Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:

**In the section "Attorney Docket No.", please delete "KRM/SJB" and insert --
JAG/KRM--;**

**In the section "Applicant(s)", please delete the second applicant's city of residence,
"Dusseldorf", and insert --Duesseldorf--; and**


**In the section "Title", please delete "Folypolyglutamyl synthetase gene transfer to
enhance antifolate", and insert --Folylpolyglutamyl Synthetase Gene Transfer to Enhance
Antifolate Drug Sensitivity--.**

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: December 14, 2000

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\ATERRY\0609\483-1\correct ofr
SKGF Rev. 10/11/00 mac



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/617,116	07/14/2000	1614	420	0609.4830001/KRM/JB	6	JAG/KRM	
						FILING RECEIPT	
						 *OC000000005601457*	RECEIVED MAR 06 2001 HIGH CENTER 1600/2900

Karen R. Markowicz
Sterne Kessler Goldstein & Fox PLLC
1100 New York Avenue N W
Suite 600
Washington, DC 20005



Date Mailed: 12/06/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Manish Aghi, Brookline, MA ;
 Christof M. Kramm, ~~Dusseldorf~~, GERMANY;
 Xandra O. Breakefield, Newton, MA ;

DUESSELDORF DEC 12 2000

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/144,074 07/16/1999

12/12
12/12
12/12 days

Foreign Applications

JAG
KRM

KRM 12/12

If Required, Foreign Filing License Granted 09/19/2000

**** SMALL ENTITY ****

Title

L
 Polypolyglutamyl synthetase gene transfer to enhance antifolate

DRUG SENSITIVITY

Preliminary Class

514

Data entry by : ZIMMERMAN, SHAUNA

Team : OIPE

Date: 12/06/2000



RECEIVED

MAR 08 2001

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- o The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- o The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- o The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- o The docket number allows a maximum of 25 characters.
- o If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- o The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

TECH CENTER 1600/2900

MAR 6 2001

RECEIVED

RECEIVED

MAR 08 2001

TECH CENTER 1600/2900



H.S.
FILE COPY
UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov


Bib Data Sheet

SERIAL NUMBER 09/617,116	FILING DATE 07/14/2000 RULE	CLASS 514	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. 0609.4830001/JAG/KRM
-----------------------------	---------------------------------------	--------------	------------------------	---

APPLICANTS

Manish Aghi, Brookline, MA ;
 Christof M. Kramm, Duesseldorf, GERMANY;
 Xandra O. Breakefield, Newton, MA ;

**** CONTINUING DATA *******

THIS APPLN CLAIMS BENEFIT OF 60/144,074 07/16/1999

**** FOREIGN APPLICATIONS *******
**IF REQUIRED, FOREIGN FILING LICENSE
GRANTED ** 09/19/2000**
**** SMALL ENTITY ****

Foreign Priority claimed	<input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY MA	SHEETS DRAWING 6	TOTAL CLAIMS 11	INDEPENDENT CLAIMS 1
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials			

ADDRESS

Karen R. Markowicz
 Sterne Kessler Goldstein & Fox P L L C
 1100 New York Avenue N W
 Suite 600
 Washington ,DC 20005

TITLE

Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity

FILING FEE RECEIVED 420	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit